Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial

Diabetes Care

Volumn 38, Issue 6, 2015, Pages 1145-1153

  Leiter, Lawrence A ^a   Teoh, Hwee ^a   Braunwald, Eugene ^b   Mosenzon, Ofri ^c   Cahn, Avivit ^c   Kumar, K M Prasanna ^d   Smahelova, Alena ^e   Hirshberg, Boaz ^f   Stahre, Christina ^g   Frederich, Robert ^h   Bonnici, Francois ⁱ   Scirica, Benjamin M ^b   Bhatt, Deepak L ^b   Raz, Itamar ^c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d AOUniversitaria Senese   (India)

^e CHARLES UNIVERSITY   (Czech Republic)

^f ASTRAZENECA   (United Kingdom)

^g ASTRAZENECA R AND D   (Sweden)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ Groote Schuur Hospital and UCT Private Academic Hospital   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; PLACEBO; SAXAGLIPTIN; ADAMANTANE; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ACUTE PANCREATITIS; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CHRONIC PANCREATITIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HAZARD RATIO; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; URINARY TRACT INFECTION; VERY ELDERLY; ADULT; ANALOGS AND DERIVATIVES; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHY; DOSE RESPONSE; DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; INCIDENCE; METABOLISM; MIDDLE AGED; MORTALITY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADAMANTANE; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART FAILURE; HEMOGLOBIN A, GLYCOSYLATED; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; STROKE; TREATMENT OUTCOME;

EID: 84941907172     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-2868     Document Type: Article

References (42)

1. International Diabetes Federation. IDF Diabetes Atlas. 6th ed. Brussels, Belgium, International Diabetes Federation, 2013.
2. Arnett DK, Goodman RA, Halperin JL, Anderson JL, Parekh AK, Zoghbi WA. AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and U.S. Department of Health and Human Services. J Am Coll Cardiol 2014;64:1851-1856.
3. Cruz-Jentoft AJ, Carpena-Ruiz M, Montero- Errasqúin B, Śanchez-Castellano C, Śanchez- Garćia E. Exclusion of older adults from ongoing clinical trials about type 2 diabetes mellitus. J Am Geriatr Soc 2013;61:734-738.
4. Lakey WC, Barnard K, Batch BC, Chiswell K, Tasneem A, Green JB. Are current clinical trials in diabetes addressing important issues in diabetes care? Diabetologia 2013;56:1226-1235.
5. Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. Diabetes Care 2012;35: 2650-2664.
6. Cheng AY; Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction. Can J Diabetes 2013;37(Suppl. 1):S1-S3.
7. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379.
8. Sinclair A, Morley JE, Rodriguez-Manas L, et al. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International TaskForce of Experts in Diabetes. J AmMed Dir Assoc 2012;13:497-502.
9. Sarwar N, Gao P, Seshasai SR, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies [published correction appears in Lancet 2010;376:958]. Lancet 2010;375: 2215-2222.
10. Huang ES, Laiteerapong N, Liu JY, John PM, Moffet HH, Karter AJ. Rates of complications and mortality in older patients with diabetes mellitus: The diabetes and aging study. JAMA Intern Med 2014;174:251-258.
11. U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research. Guidance for Industry. Diabetes MellitusdEvaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. Silver Spring, MD, Food and Drug Administration, 2008.
12. Mosenzon O, Raz I, Scirica BM, et al. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial. Diabetes Metab Res Rev 2013;29:417-426.
13. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326.
14. Scirica BM, Bhatt DL, Braunwald E, et al. The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 study. Am Heart J 2011;162:818-825.
15. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-559.
16. European Medicines Agency. Guideline on Clinical Investigation of Medicinal Products in the Treatment of Diabetes Mellitus. London, European Medicines Agency, 2012 (CPMP/EWP/1080/00 Rev. 1 ed).
17. Miller ME, Williamson JD, Gerstein HC, et al.; ACCORD Investigators. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care 2014;37:634-643.
18. Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle HJ. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Lancet 2013;382:1413-1423.
19. Barzilai N, Guo H, Mahoney EM, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011;27:1049-1058.
20. Doucet J, Chacra A, Maheux P, Lu J, Harris S, Rosenstock J. Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin 2011;27:863-869.
21. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012;344:e1369.
22. Karyekar CS, Ravichandran S, Allen E, Fleming D, Frederich R. Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged $65 years) with inadequately controlled type 2 diabetes mellitus. Clin Interv Aging 2013;8:419-430.
23. Monami M, Ahŕen B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;15:112-120.
24. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011;27(Suppl. 3):57- 64.
25. Pratley RE, McCall T, Fleck PR, Wilson CA, Mekki Q. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc 2009;57:2011-2019.
26. Pratley RE, Rosenstock J, Pi-Sunyer FX, et al. Management of type 2 diabetes in treatmentnaive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care 2007; 30:3017-3022.
27. Schweizer A, Dejager S, Foley JE, Shao Q, Kothny W. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population $75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab 2011;13:55-64.
28. Schwartz SL. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother 2010;8:405-418.
29. Gilbert MP, Pratley RE. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. Am J Med 2009;122(Suppl.):S11-S24.
30. Barnett AH, Charbonnel B, Li J, Donovan M, Fleming D, Iqbal N. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. Clin Drug Investig 2013;33:707-717.
31. Hirshberg B, Parker A, Edelberg H, Donovan M, Iqbal N, Mosenzon O. Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2014;30:556-569.
32. Engel SS, Round E, Golm GT, Kaufman KD, Goldstein BJ. Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies. Diabetes Ther 2013;4: 119-145.
33. Raz I, Cahn A, Scirica BM, et al. Predisposing factors for hypoglycemia: analysis from the SAVOR TIMI 53 trial. Diabetologia 2014;57:S263.
34. Leese GP, Wang J, Broomhall J, et al.; DARTS/MEMO Collaboration. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003;26:1176-1180.
35. Munshi MN, Segal AR, Suhl E, et al. Frequent hypoglycemia among elderly patients with poor glycemic control. Arch Intern Med 2011;171:362-364.
36. Gregg EW, Engelgau MM, Narayan V. Complications of diabetes in elderly people. BMJ 2002;325:916-917.
37. Rosenstock J, Marx N, Kahn SE, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res 2013;10:289-301.
38. Sicras-Mainar A, Navarro-Artieda R. Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly. Drug Des Devel Ther 2014;8:811-818.
39. Green JB, BethelMA, Paul SK, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J 2013;166:983-989.
40. Bi Y, Zhu D, Cheng J, et al. The status of glycemic control: a cross-sectional study of outpatients with type 2 diabetes mellitus across primary, secondary, and tertiary hospitals in the Jiangsu province of China. Clin Ther 2010; 32:973-983.
41. Leiter LA, Berard L, Bowering CK, et al. Type 2 diabetes mellitus management in Canada: is it improving? Can J Diabetes 2013;37:82-89.
42. Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care 2013;36:2271-2279.